Just another Network site

The CEO of a $12 billion biotech startup explains why he didn’t look to Silicon Valley for backing

A biotech startup with a $12 billion valuation didn't look to Silicon Valley for backing

  • The CEO of a $12 billion biotech startup explains why he didn’t look to Silicon Valley for backing
  • The startup has already reportedly reached a $12 billion valuation, much higher than most early-stage biotech companies.
  • RELATED: An experimental treatment wants to harness the power of stem cells to treat baldness

Read the full article, click here.


@businessinsider: “A biotech startup with a $12 billion valuation didn’t look to Silicon Valley for backing”


Samumed CEO Osman Kibar spoke to CNBC about its valuation and the company’s goal to provide “disease-modifying” treatments.


The CEO of a $12 billion biotech startup explains why he didn’t look to Silicon Valley for backing

Comments are closed, but trackbacks and pingbacks are open.